25 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
22496391	40	Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.	Bristol-Myers Squibb Research
22930276	25	Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.	Amgen
23371965	1	The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.	University Of Michigan Medical School
22613176	1	Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen.	Pacific University Oregon
25415535	118	Inhibitors of c-Jun N-terminal kinases: an update.	Eberhard Karls Universit£T T£Bingen
25441013	49	Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.	Vertex Pharmaceuticals
24694071	11	New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.	Micurx Pharmaceuticals
24900630	16	Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.	University Of Cape Town
23896611	16	Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.	University Of Cape Town
23810496	31	Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.	Korea Research Institute Of Chemical Technology
16248836	154	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	F. Hoffmann-La Roche
22784008	100	Synthesis and biological evaluation of the 1-arylpyrazole class ofs(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).	Esteve
22708876	106	Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.	Merck Research Laboratories
22239545	287	Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.	Amgen
18345609	57	Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.	The Institute Of Cancer Research
17630726	32	Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.	Novartis Institutes For Biomedical Research
15634016	232	5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.	Human Biomolecular Research Institute
21978946	45	Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.	Takeda Pharmaceutical
21411321	28	Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.	Merck Research Laboratories
19810674	93	Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B	Universita Degli Studi Di Bari
17399990	45	In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).	Université